Formulation of Proteins for Pulmonary Delivery

Protein Formulation and Delivery, Second Edition

Volumn , Issue , 2007, Pages 219-254

  Clark, Andrew R ^a   Stevenson, Cynthia L ^a   Shire, Steven J ^b  

^a NEKTAR THERAPEUTICS   (United States)

^b GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79955604996     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.3109/9780849379529-13     Document Type: Chapter

References (113)

1. Clarke S, Stephenson RC, Lowenson JD, Ahern TJ, Manning MC. Stability of protein pharmaceuticals. Part A. Chemical and physical pathways of protein degradation. In: Ahern TJ, Manning MC, eds. Pharmaceutical Biotechnology. Vol. 2. New York: Plenum Press, 1992:434.
2. Cleland JL, Powell M, Shire SJ. The development of stable protein formulations: a close look at protein aggregation, deamidation and oxidation. Crit Rev Ther Drug Carrier Sys 1994; 10(4):307-377.
3. Guidance for Industry; Nasal spray and inhalation solution, suspension and spray drug products—chemical, manufacturing and control documentation. Federal Drug Administration Center for Drug Evaluation and Research (CDER), July 2002. (http://www.fda.gov/cder/guidance/4234fnl.htm)
4. Gonda I. Physiochemical principles in aerosol delivery. In: Crommelin DJA, ed. Topics in Pharmaceutical Sciences. 1991. Stuttgard: Medpharm Scientific.
5. Byron PR. Aerosol formulation, generation, and delivery using nonmetered systems. In: Byron PR, ed. Respiratory Drug Delivery III. Boca Raton: CRC Press, 1990:143-165.
6. Rudolf G, Gebhart J, Heyder J, Scheuch G, Stahlhofen W. Mass deposition from inspired polydisperse aerosols. Ann Occup Hyg 1988; 32:919-938.
7. Proceedings of International Society for Aerosols in Medicine Focused Symposium. Towards Meaningful Laboratory Tests for Evaluation of Pharmaceutical Aerosols, Puerto Rico, Jamaica. 29-31, 1997; J Aerosol Med 11 (1998).
8. Ranucci J. Dynamic plume-particle size analysis using laser diffraction. Pharm Technol 1992; 16(10):109-114.
9. Gorman WG, Carroll FA. Aerosol particle-size determination using holography. Pharm Technol 1993; 17(2):34-37.
10. Jager PD, De Stefano GA, Mcnamara DP. Particle size measurement using right-angle light scattering. Pharm Technol 1993; 17(4):102-120.
11. Ranucci JA, Chen CF. Phase doppler anemometry: a technique for determining aerosol plume-particle size and velocity. Pharm Technol 1993; 17(6):62-74.
12. Niven RW. Aerodynamic particle size testing using a time-of-flight aerosol beam spectrometer. Pharm Technol 1993; 17(l):72-78.
13. Clark AR. The use of laser diffraction for the evaluation of the aerosol clouds generated by medical nebulizers. Int J Pharm 1995; 115:69-78.
14. Milosovich SM. Particle size determination via cascade impaction. Pharm Technol 1992; 16(9):82-86.
15. Atkins PJ. Aerodynamic particle size testing—impinger methods. Pharm Technol 1992; 16(8):26-32.
16. USP/NF. Physical tests and determinations: Aerosols, Vol. USO XVII. IUSPharmacopeia. Rockville, MD: United States Pharmacopeial Convention, Inc., 1992:3158-3178.
17. European Pharmacopeia. Section 2.9.18—Preparations for inhalation: aerodynamic assessment of fine particles. European Pharmacopeia. 5th ed. (suppl 1). Council of Europe, 67075 Strasbourg, France, 2005:2799-2811.
18. USP 28-NF 23. Physical tests and determinations: Aerosols. Rockville, MD, USA: United States Pharmacopeia, 1992:3298-2316.
19. Lundback HH, Bagger-Jorgensen H, Sandell D, Sundahl M. Effect of inherent variability of inhalation products on impactor mass balance limits. In RN Dalby, PR Byron and SJ Far (eds) Respiratory Drug Delivery Europe, Interpharm press, Buffalo Griove, 2005; 1:177-180.
20. Pritchard SE, Mc Robbie DW. Studies of human oropharyngeal airspaces using magnetic resonance imaging—II. The use of 3D gated MRI to determine the influence of mouthpiece diameter and resistance of inhaled delivery systems on the orophayngeal airspace geometry. J Aerosol Med 2003; 17(4):310-324.
21. Cipolla DC, Gonda I. Method for collection of nebulized proteins. In: Cleland JL, Langer R, eds. Formulation and Delivery of Proteins and Peptides. Washington: American Chemical Society, 1994:342-352.
22. Niven RW, Butler JP, Brain JD. How air jet nebulizers may damage ‘sensitive’ drug formulations. 11th Annual Meeting of the American Association for Aerosol Research, San Francisco, Oct 12-16, 1992.
23. Niven RW. Delivery of biotherapeutics by inhalation aerosols. Pharm Technol 1993; 17(7):72-81.
24. Cipolla DC, Clark AR, Chan HK, Gonda I, Shire SJ. Assessment of aerosol delivery systems for recombinant human deoxyribonuclease. STP Pharma Sci 1994; 4(l):50-62.
25. Newman SP, Steed KP, Reader JS, Hooper G, Zierenberg B. Efficient delivery to the lungs of flunisolide aerosol from a new portable hand-held multidose nebulizer. J Pharm Sci 1996; 85(9):960-964.
26. Cipolla D, Gonda I, Shire SJ. Characterization of aerosols of human recombinant deoxyribonuclease I (rhDNase) generated by jet nebulizers. Pharm Res 1994; 11:491-498.
27. Ivri E. Apparatus and methods for delivery of therapeutic liquids to the respiratory system. U.S. patent 5,586,500, 1996.
28. Keller M, Lintz FC, Walther E. Novel liquid formulation technologies as a tool to design the aerosols performance of nebulizers using air jet (LC plus) or a vibrating membrane principle (E-Flow). Drug Delivery to the Lungs, London, Dec 13-14, 2001.
29. Schuster J, Rubsamen R, Lloyd P, Lloyd J. The AERx aerosol delivery system. Pharm Res 1997; 14(3):354-357.
30. Newman SP, Steed K, Towse L, Zierenberg B. The BINEB (final prototype): a novel hand-held multidose nebuliser evaluated by gamma scintigraphy. Eur Respir J 1996; 9:441S.
31. Weston TE, King AW, Dunne ST. Atomising devices and methods. World Intellectual Property Organization. Dunne Miller Weston Ltd., 1991. Patent WO 91/14468.
32. Fine JM, Gordon T, Thompson JE, Sheppard D. The role of titratable acidity in acid aerosol-induced broncho-constriction. Am Rev Respir Dis 1987; 135:826-830.
33. Balmes JR, Fine JM, Christian D, Gordon T, Sheppard D. Acidity potentiates bronchoconstriction induced by hypoos-molar aerosols. Am Rev Respir Dis 1988; 138:35-39.
34. Beasley R, Rafferty P, Holgate ST. Adverse reactions to the non-drug constituents of nebulizer solutions. Br J Clin Pharmacol 1988; 25:283-287.
35. Desager KN, Van Bever HP, Stevens WJ. Osmolality and pH of anti-asthmatic drug solutions. Agents Actions 1990; 31:225-228.
36. Snell NJC. Adverse reactions to inhaled drugs. Resp Med 1990; 84:345-348.
37. Sant’Ambrogio G, Andersen JW, Sant’Ambrogio FP, Mathew OP. Response to laryngeal receptors to water solutions of different osmolality and ionic composition. Respir Med 1991; 85(A):57-60.
38. Gonda I, Kayes JB, Groom CV, Fildes FJT. Characterization of hygroscopic inhalation aerosols. In: Stanley-Wood NG, ed. Particle Size Analysis. New York: Wiley Heyden, 1982:31-34.
39. Gonda I, Phipps PR. Some consequences of instability of aqueous aerosols produced by jet and ultrasonic nebulizers. In: Masuda S, Takahashi K, eds. Aerosols. New York: Pergamon Press, 1991:227-230.
40. Godden DJ, Borland C, Lowry R, Higgenbottam TW. Chemical specificity of coughing in man. Clin Sci 1986; 70:301-306.
41. Auffarth B, De Monchy JG, van der Mark TW, Postma DS, Koeter GH. Citric acid cough threshold and airway responsiveness in asthmatic patients and smokers with chronic airflow obstruction. Thorax 1994; 46:638-642.
42. Cipolla D, Gonda I, Meserve KC, Weck S, Shire SJ. Formulation and aerosol delivery of recombinant deoxyribonucleic acid derived human deoxyribonuclease I. In: Cleland JL, Langer R, eds. Formulation and Delivery of Proteins and Peptides. ACS Symposium Series 567.Washington: American Chemical Society, 1994:322-342.
43. Tanford C. The Hydrophobic Effect. New York: Wiley, 1980.
44. Oeswein JQ et al. Aerosolization of protein pharmaceuticals. Proceedings of the Second Respiratory Drug Delivery Symposium, University of Kentucky, 1991.
45. Hora MS, Rana RK, Wilcox CL, Katre NV, Hirtzer P, Wolfe SN, Thomson JW. Development of a lyophilized formulation of interleukin-2. Dev Biol Stand 1992; 74:295-306.
46. Lam XM, Patapoff TW, Nguyen TH. The effect of benzyl alcohol on recombinant human interferon-gamma. Pharm Res 1997; 14(6):725-729.
47. Beasley R, Rafferty P, Holgate S. Benzalkonium chloride and bronchoconstriction [letter]. Lancet 1986; 2(8517):1227.
48. Berg OH, Henriksen RN, Steinsvag SK. The effect of a benzalkonium chloride-containgin nasal spray on human respiratory mucosa in vitro as a function of concentration and time of action. Pharmacol Toxicol 1995; 76(4):245-249.
49. Klaustermeyer WB, Hale FC, Prescott EJ. Reproducibility of the response to diluent challenge in adult asthma. Ann Allergy 1979; 43(2):84-87.
50. Wright W, Zhang YG, Salome CM, Woolcock AJ. Effect of inhaled preservatives on asthmatic subjects. I. Sodium metabisulfite. Am Rev Respir Dis 1990; 141(6):1400-1404.
51. Zhang YG, Wright WJ, Tam WK, Nguyen-Dang TH, Salome CM, Woolcock AJ. Effects of inhaled preservatives on asthmatic subjects, II. Benzalkonium chloride. Am Rev Respir Dis 1990; 141:1405-1408.
52. Stadtman R. Metal ion-catalyzed oxidation of proteins: biochemical mechanism and biological consequences. Free Radical Biol Med 1990; 9(4):315-325. (Erratum published in Free Radical Biol Med 1991; 10:3-48.)
53. Patton JS, Platz RM. Aerosol insulin—a brief review. In: Byron PR, Dalby RN, Farr SJ, eds. Respiratory Drug Delivery IV. Buffalo Grove: Interpharm Press, 1994:65-74.
54. Chang, J Y H, Milby T, Oeswein JQ. Effects of metals and phenol on hGH degradation. Pharm Res 1994; 11(10):S81.
55. Lyda JC. FDA proposes sterility requirement of Inhalation solution drug products. PDA Let 1997:5-6.
56. Thipphawong J, Toulana B, Clauson P, Okikawa J, Farr SF. Pulmonary insulin administration using the AERx insulin diabetes system. Diabetes Technol Ther 2002; 4:499-504.
57. Leung FK, Li J, Song Y, et al. Glucose responses of pulmonary-delivered alveair formulated with unmodified chinese-made analog insulin in normal rats. ADA 65 th Scientific Session, 2005, 2058-P0.
58. ® [Package insert]. New York: Pfizer Inc, 2006.
59. Lee VHL, Dodda-Kashi S, Grass GM, Rubas W. Oral route of peptide and protein drug delivery. In: Lee VHL, ed. Peptide and Protein Drug Delivery. New York: Marcel Dekker, 1991:891.
60. Eljamal M, Nagarajan S, Patton JS. In situ and in vivo methods for pulmonary delivery. Pharm Biotechnol 1996; 8:361-374.
61. Rudolph G, Kobirch R, Stahlhofen W. Modeling and algebraic formation of regional aerosol deposition in man. J Aerosol Sci 1990; 21(l):S306-S406.
62. Woiszwillo JE, Fothstein F. Method for isolating biomolecules from a biological sample with linear polymers. US Patent 5,599,719, 1997.
63. Steiner S, Pfutzner A,Wilson BR, Harzer O, Heinemann L, Rave K. Technosphere/ insulin proof of concept study with a new insulin formulation for pulmonary delivery. Exp Clin Endocrinol Diabetes 2002; 110:1721.
64. Edwards DA, Hanes J, Caponetti G, et al. Large porous particles for pulmonary drug delivery. Science 1997; 276(5320):1868-1871.
65. Dellamary LA, Tarara TE, Smith DJ, et al. Hollow porous particles for inhalation. Pharm Res 2000; 17:168-174.
66. Lechuga-Ballesteros D, Charan C, Liang Y, Stults CLM, Vehring R, Kuo M. Designing stable and high performance respirable particles of pharmaceuticals. In: Dalby R, Byron P, eds. Respiratory Drug Delivery IX. Buffalo Grove: Interpharm Press, 2004:565-568.
67. Chan HK, Clark A, Gonda I, Mumenthaler M, Hsu C. Spray dried powders and powder blends of recombinant human deoxyribonuclease (rhDNase) for aerosol delivery. Pharm Res 1997; 14:431.
68. Visser J. An invited review: van der waals and other cohesive forces affecting powder fluidization. Powder Technol 1989; 58:1-10.
69. Lechuga-Ballesteros D, Charan C, Stults CLM,et al. Trileucine improves aerosol performance and stability of spray-dried powders for inhalation. J Pharm Sci. in-press.
70. Clark AR, Dasovich N, Gonda I, Chan HK. The balance between biochemical and physical stability for inhalation protein powder: rhDNase as an example. In: Dalby R, Byron P, eds. Respiratory Drug Delivery V. Buffalo Grove: Interpharm Press, 1996:167.
71. Carpenter JF, Prestrelski SJ, Anchordoquy T, Arakawa T. Interactions of stabilizers with proteins during freezing and drying. In: Cleland JL, Langer R, eds. Formulation and Delivery of Proteins and Peptides. ACS Symposium Series 567. Washington: American Chemical Society, 1994:134-147.
72. Franks F, Hatly RH. Storage of materials. US patents 5,098,893, 1992.
73. Levine H, Slade L. Another view of trehalose for drying and stabilizing biological materials. Biopharm 1992; 5:36.
74. French DL, McAuly AJ, Chang B, Niven RW. Moisture induced state changes in spray-dried trehalose/protein formulations. Pharm Res 1995; 12(9):S-83.
75. Lechuga-Ballesteros D, Abdul-Fattah A, Stevenson CL, Bennett DB. Properties and stability of a liquid crystal form of cyclosporine: the first reported naturally occurring peptide that exists as a thermotropic liquid crystal. J Pharm Sci 2003; 92:1821-1831.
76. Lechuga-Ballesteros D, Bennett D, Cabot K, et al. Aerosol drug development of a spray dried liquid crystalline formulation of cyclosporine. In: Dalby R and Byron P, eds. Respiratory Drug Delivery VII. Rayleigh: Serentec Press, 2000:147-256.
77. Quan C, Wu S, Hsu C, Canova-Davis E. Title. Ninth Symposium of the Protein Society, Boston, 1995.
78. Wolf R. The safety of inhaled therapeutic proteins. J Aerosol Med 1998; 11(4):197-219.
79. Anderson SD, Brannan J, Spring J, et al. A novel bronchial provocation test (BPT) using a respirable dry powder of mannitol. Australian and New Zealand thoracic Society ASM. Perth, Australia, 1996.
80. Platz R. Improved process for preparing micronized polypeptide drugs. WO93/13752, 1993.
81. Chang BS, Fischer NL. Development of an efficient single-step freeze-drying cycle for protein formulations. Pharm Res 1995; 12:831-837.
82. Mumenthaler M, Hsu CC, Pearlman R. Feasibility study on spray-drying protein pharmaceuticals: recombinant human growth hormone and tissue type plasminogen activator. Pharm Res 1994; 11:12-20.
83. Maa YF, Nguyen PAT, Hsu SW. Spray drying of air-liquid interface sensitive recombinant human growth hormone. J Pharm Sci 1998; 87:152-159.
84. Yang B, Lesikar D, Tan MM, Ramchandran S, Stevenson CL. Formulation of human growth hormone for pulmonary delivery. AAPS PharmSci 2002; 4:W5073.
85. Nguyen XC, Herberger JD, Burke PA. Protein powders for encapsulation: a comparison of spray-freeze-drying and spray drying of darbepoetin alfa. Pharm Res 2004; 21:507-514.
86. Vanbever R, Mintzes JD, Wang J, et al. Formulation and physical characterization of large porous particles for inhalation. Pharm Res 1999; 16:1735-1742.
87. Chan HK, Clark AR, Feeley JC, et al. Physical stability of salmon calcitonin spray dried powders for inhalation. J Pharm Sci 2004; 93:792-804.
88. Owens DR, Zinman B, Bolli GB. Insulins today and tomorrow. Lancet 2001; 358:589-597.
89. Pfuztner A, Mann AE, Steiner SS. Technosphere/insulin—a new approach for effective delivery of human insulin via the pulmonary route. Diabetes Technol Ther 2002; 4:589-593.
90. Heinemann L, Pfutzner A, Heise T. Alternative routes of administration as an approach to improve insulin therapy: update on dermal, oral, nasal and pulmonary insulin delivery. Curr Pharm Des 2002; 7:1327-1352.
91. Pfutzer A, Flacke F, Pohl R, et al. Pilot study with technosphere/PTH (1-34)—a new approach for effective pulmonary delivery of parathyroid hormone (1-34). Horm Metab Res 2003; 35:319-323.
92. Niven RW, Lott FD, Ip AY, Crips KM. Pulmonary delivery of powders and solutions containing recombinant human granulocyte colony-stimulating factor (rhG-CSF) in the rabbit. Pharm Res 1994; 11:1101-1109.
93. Shahiwala A, Misra A. A preliminary pharmacokinetic study of liposomal leuprolide dry powder inhaler: a technical note. AAPS PharmSciTech 2005; 6:E482-E486.
94. Bosquillon C, Preat V, Vanbever R. Pulmonary delivery of growth hormone using dry powders and visualization of its focal fate in rats. J Control Release 2004; 96:233-244.
95. Maa YF, Nguyen PA, Andya JD, et al. Effect of spray drying and subsequent processing conditions on residual moisture content and physical/biochemical stability of protein inhalation powders. Pharm Res 1998; 15:768-775.
96. Maa YF, Nguyen PA, Sweeney T, Shire SJ, Hsu CC. Protein inhalation powders: spray drying vs spray freeze-drying. Pharm Res 1999; 16:249-254.
97. Hausmann M, Bellweg S, Heinemann L, Buchwald A, Heise T. Add-on therapy with Kos inhaled insulin dosed using a metered dose inhaler is as efficacious as add-on therapy with Lantus in poorly controlled type 2 diabetic patients treated with sulfo-nylureas or metformin. ADA 65th Scientific Sessions, 417-OR, 2005.
98. Brown R, Slusser JG. Propellant-driven aerosols of functional proteins as potential therapeutic agents in the respiratory tract. Immunopharmacology 1994; 28:241-257.
99. Brown R, Pickrell JA. Propellant-driven aerosols for delivery of proteins in the respiratory tract. J Aerosol Med 1995; 8(1):43-57.
100. ®, (Dornase Alpha)] In: Pearlman R, Wang J, eds. Formulation, Characterization, and Stability of Protein Drugs. New York: Plenum Press, 1996.
101. White S, Bennett DB, Cheu S, et al. Exubera: pharmaceutical development of a novel product for pulmonary delivery of insulin. Diabetes Technol Ther 2005; 7:896-906.
102. Skyler SJ, Cefalu WT, Kourides IA, et al. Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomized proof-of-concept study. Lancet 2001; 357:331-335.
103. Hancock BC, Shablin SL, Zografi G. Molecular mobility of amorphous pharmaceutical solids below their glass transition temperatures. Pharm Res 1991; 12:799-806.
104. Franks F, Hatley RHM, Mathias SF. Materials science and the production of shelf-stable biologicals. Pharm Technol Int 1991; 3:24-34.
105. Hancock BC, Zografi G. The relationship between glass transition temperature and the water content of amorphous pharmaceutical solids. Pharm Res 1994; 11:471-477.
106. Kajiwara K, Franks F, Echlin P, Greer AL. Structural and dynamic properties of crystalline and amorphous phases in raffinose-water mixtures. Pharm Res 1999; 16:1441-1448.
107. Strickley RG, Anderson BD. Solid state stability of human insulin. II. Effect of water on reactive intermediate partitioning in lyophilizes from pH 2-5 solution stabilization against covalent dimer formation. J Pharm Sci 1997; 86:645-653.
108. Tahl K, Claesson M, Lilliehorn P, Linden H, Backstrom K. The effect of process variables on the degradation and physical properties of spray dried insulin intended for inhalation. Int J Pharm 2002; 233:227-237.
109. Adjei A, Sundberg D, Miller J, Chun A. Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans. Pharm Res 1992; 9:244-249.
110. Zheng JY, Fulu MY, Lee DY, Barber T, Adjei AL. Pulmonary peptide delivery: effect of taste-masking excipients on leuprolide suspension metered dose inhalers. Pharm Dev Tech 2001; 6:521-530.
111. Adjei L, Garren J. Pulmonary delivery of peptide drugs: effect of particle size on bioavailabiltiy of leuprolide acetate in healthy male volunteers. Pharm Res 1990; 7(6):565-569.
112. Adjei L, Carrigan PJ. Pulmonary bioavailability of LH-RH analogs: some biophar-maceutical guidelines. J Biopharm Sci 1992; 3(l/2):247-254.
113. Clark AR. MDIs: the physics of aerosol formation. J Aerosol Med 1996; 9(1): S19-S25.